215 related articles for article (PubMed ID: 2551985)
1. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
2. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Cadroy Y; Hanson SR; Harker LA
Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989
[TBL] [Abstract][Full Text] [Related]
4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
5. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
[TBL] [Abstract][Full Text] [Related]
6. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222.
Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR
Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
9. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
10. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
[TBL] [Abstract][Full Text] [Related]
11. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
Kaiser B; Hauptmann J; Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism.
Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M
Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427
[TBL] [Abstract][Full Text] [Related]
13. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Cadroy Y; Hanson SR; Harker LA
Arterioscler Thromb; 1993 Aug; 13(8):1213-7. PubMed ID: 8343496
[TBL] [Abstract][Full Text] [Related]
14. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
15. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
[TBL] [Abstract][Full Text] [Related]
16. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
[TBL] [Abstract][Full Text] [Related]
17. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
[TBL] [Abstract][Full Text] [Related]
18. The influence of low molecular weight heparin in combination with dihydroergotamine on experimental thrombosis and haemostasis.
Bergqvist D; Nilsson B
Thromb Haemost; 1987 Oct; 58(3):893-5. PubMed ID: 2829377
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
